Guidelines for clinical management of bioterrorism bacterial diseases: Anthrax, plague, turalemia and brucellosis;Bases para el manejo médico de enfermedades bacterianas potencialmente implicadas en bioterrorismo: Ántrax, peste, tularemia y brucelosis

Anales de Medicina Interna

Volumn 20, Issue 10, 2003, Pages 540-547

  Eiros Bouza, J M ^a,b   Bachiller Luque, M R ^a   Ortiz De Lejarazu, R ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; PLAGUE VACCINE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE DERIVATIVE;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BIOLOGICAL WARFARE; BREATHING APPARATUS; BRUCELLOSIS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; DISEASE TRANSMISSION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; MICROBIOLOGICAL EXAMINATION; PLAGUE; PRACTICE GUIDELINE; REVIEW; TULAREMIA; VACCINATION; YERSINIA PESTIS;

ANTHRAX; BIOTERRORISM; BRUCELLOSIS; HUMANS; PLAGUE; TULAREMIA;

EID: 0242389572     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Schultz CH, Mothershead JL, Field M. Bioterrorism preparedness. I: The emergency department and hospital. Emerg Med Clin North Am 2002; 20: 437-455.
2. Flowers LK, Mothershead JL, Blackell TH. Bioterrorism preparedness. II: The community and emergency medical services systems. Emerg Med Clin North Am 2002; 20: 457-476.
3. Mothershead JL, Tonant K, Koenig KL. Bioterrorism preparedness. III: State and federal program and response. Emerg Med Clin North Am 2002; 20: 477-500.
4. Varkey P, Poland GA, Cockerill FR 3rd, Smith TF, Hagen PT. Confronting bioterrorism: physicians on the front line. Mayo Clin Proc 2002; 77: 661-672.
5. Meyer RF, Morse SA. Bioterrorism preparedness for the public health and medical communities. Mayo Clin Proc 2002; 77: 619-621.
6. Greenfield RA, Drevets DA, Machado LJ, Voskuhl GW, Cornea P, Bronze MS. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci 2002; 323: 299-315.
7. Jones J, Terndrup TE, Franz DR, Eitzen EM Jr. Future challenges in preparing for and responding to bioterrorism events. Emerg Med Clin North Am 2002; 20: 501-524.
8. Evans RG, Crutcher JM, Shadel B, Clements B, Bronze MS. Terrorism a public health perspective. Am J Med Sci 2002; 323: 291-298.
9. Eiros Bouza JM, Espinosa Parra FJ, Moreno Guillén S. La rotación en enfermedades infecciosas. Med Clin (Barc) 1989; 93: 39.
10. Shannon M, Burstein J, Mandl K, Fleisher G. Usage of a web-based decision support tool for bioterrorism detection. Am J Emerg Med 2002; 20: 384-385.
11. Bouza E. Aproximación general al diagnóstico del paciente potencialmente infectado. En: Foz A, Roy C, eds. Patología Infecciosa Básica-Medicine. Idepsa. Madrid, 1989: 10-14.
12. Eiros JM; Rodríguez Torres A. Infecciones en Unidades de Cuidados Intensivos. En: Conceptos actuales en Enfermedades Infecciosas y Microbiología Clínica, 1. Infección Nosocomial. Picazo de la Garza JJ, Romero Vivas J, eds. Ediciones Doyma SA. Barcelona, 1992: 59-76.
13. Eiros JM, Hernández B, Landínez R, Fernández Calvo J. Infecciones en el paciente neutropénico. Forhos 2000; 3: 5-15.
14. Schmitt SK, Mehta N. Systematic reviews of infectious diseases. Clin Infect Dis 2002; 34: 1515-1523.
15. Eiros Bouza JM, Martínez P, Ortiz de Lejarazu R. Procesamiento de muestras clínicas para el análisis microbiológico. Técnicas de Laboratorio 1998; 229: 117-123.
16. Pavlin JA, Gichrist MJ, Osweiler GD, Woollen NE. Diagnostic analyses of biological agent-caused syndromes: laboratoty and technical assisstance. Emerg Med Clin North Am 2002; 20: 331-350.
17. Darling RG, Catlett CL, Huebner KD, Jarrett DG. Threats in bioterrorism. I: CDC category A agents. Emerg Med Clin North Am 2002; 20: 273-309.
18. Moran GJ. Threats in bioterrorism. II: CDC category B and C agents. Emerg Med Clin North Am 2002; 20: 311-330.
19. Atlas RM. Bioterrorism: before and after september 11. Crit Rev Microbiol 2001; 27: 355-379.
20. Mourez M, Lacy DB, Cunningham K, Legmann R, Sellman BR, Mogridge J et al. 2001: a year of major advances in anthrax toxin research. Trends Microbiol 2002; 10: 287-293.
21. Whitby M, Ruff TA, Street AC, Fenner FJ. Biological agents as weapons 2: anthrax and plague. Med J Aust 2002; 176: 605-608.
22. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980; 353: 83-93.
23. Cullamar EK, Lutwick LI. Inhalational anthrax. Curr Infect Dis Rep 2002; 4: 238-243.
24. Webb GF, Blaser MJ. Mailborne transmission of anthrax: modeling and implications. Proc Natl Acad Sci USA 2002: 99: 7027-7032.
25. Brachman PS. Bioterrortism: an update with a focus on anthrax. Am J Epidemiol 2002; 155: 981-987.
26. Friedlander AM. Diagnosis and treatment of cutaneous anthrax. JAMA 2002; 288: 43-44.
27. Sirisanthana T, Brown AE. Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002; 8: 649-651.
28. Kaya A, Tasyaran MA, Erol S, Ozkurt Z, Ozkan B. Anthrax in adults and children: a review of 132 cases in Turkey. Eur J Clin Microbiol Infect Dis 2002; 21: 258-261.
29. Kiel JL, Parker JE, Alls JL, Kalns J, Holwitt EA, Stribling LJ et al. Rapid recovery and identification of anthrax bacteria from the environment. Ann N Y Acad Sci 2000; 916: 240-252.
30. Anónimo. Interim guidelines for investigation of and response to Bacillus anthracis exposures. Morb Mortal Wkly Rep 2001; 50: 987-990.
31. http://www.seimc.org/protocolos
32. Ressell G. CDC issues guidelines on illnesses associated with intentional release of biologic agents. Am Fam Physician 2001; 64: 1761-1762.
33. Larson S. Protecting against Bacillus anthracis. Occup Health Saf 2002; 71: 68-70.
34. Bellamy RJ, Freedman AR. Bioterrorism. QJM 2001; 94: 227-234.
35. Henderson DA. Bioterrorism. Int J Clin Pract 2000; 115: 32-36.
36. http://www.msc.es
37. http://www.gencat.es/sanitat
38. http://www.nih.cdc.gov
39. Hart CA, Beeching NJ. Prophylactic treatment of anthrax with antibiotics. BMJ 2001; 323: 1017-1018.
40. Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y et al. Search correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001; 69: 2888-2893.
41. Marshall E. Anthrax vaccine begins a new round of tests. Science 2002; 295: 427-429.
42. Montello MJ, Ostroff C, Frank EC, Haffer AS, Rogers JR. 2001 anthrax crisis in Washington DC: pharmacists' rol in screening patients and selecting prophylaxis. Am J Health Syst Pharm 2002: 59: 1193-1199.
43. Bull JJ, Parrish CR. Microbiology. A binding contract for anthrax. Science 2002; 297: 201-202.
44. Dykhuizen DE. Yersinia pestis: an instant species?. Trends Microbiol 2000; 8: 296-298.
45. Gage KL, Dennis DT, Orloski KA, Ettestad P, Brown TL, Reynolds PJ et al. Cases of cat-associated human plague in the Western US, 1977-1998. Clin Infect Dis 2000; 30: 893-900.
46. Hinnebusch BJ. Bubonic plague: a molecular genetic case history of the emergence of an infectious disease. J Mol Med 1997; 75: 645-652.
47. Paskewitz SM. Transmission factors for insect-vectored microorganisms. Trends Microbiol 1997; 5: 171-173.
48. Enscore RE, Biggerstaff BJ, Brown TL, Fulgham RE, Reynolds PJ, Engelthaler DM et al. Modeling relationships between climate and the frequency of human plague cases in the southwestern United States, 1960-1997. Am J Trop Med Hyg 2002; 66: 186-196.
49. Pettersson J, Holmstrom A, Hill J, Leary S, Frithz-Lindsten E, von Euler-Matell A et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 1999; 32: 961-976.
50. Radnedge L, Agron PG, Worsham PL, Andersen GL. Genome plasticity in Yersinia pestis. Microbiology 2002; 148: 1687-1698.
51. Fields KA, Nilles ML, Cowan C, Straley SC. Virulence role of V antigen of Yersinia pestis at the bacterial surface. Infect Immun 1999; 67: 5395-5408.
52. Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect Immun 2002; 70: 4092-4098.
53. Cleri DJ, Vernaleo JR, Lombardi LJ, Rabbat MS, Mathew A, Mart R et al. Plague pneumonia disease caused by Yersinia pestis. Semin Respir Infect 1997; 12: 12-23.
54. Moake JL. Thrombotic trombocytopenic purpura: the systemic clumpnig "plague", Annu Rev Med 2002; 53: 75-88.
55. Russell P, Nelson M, Whittington D, Green M, Eley SM, Titball RW. Laboratory diagnosis of plague. Br J Biomed Sci 1997; 54: 231-236.
56. Higgins JA, Ezzell J, Hinnebusch BJ, Shipley M, Henchal EA. 5' nuclease PCR assay to detect Yersinia pestis. J Clin Microbiol 1998; 36: 2284-2288.
57. Neubauer H, Meyer H, Prior J, Aleksic S, Hensel A, Splettstosser W. A combination of different polymerase chain reaction (PCR) assays for the presumptive identification of Yersinia pestis. J Vet Med B Infect Dis Vet Public Health 2000; 47: 573-580.
58. Neubauer H, Sprague LD. Hensel A, Aleksic S, Meyer H. Specific detection of plasmid Yersinia isolates by PCR. Clin Lab 2000; 46: 583-587.
59. Iqbal SS, Chambers JP, Brubaker RR, Goode MT, Valdés JJ. Detection of Yersinia pestis using branched DNA. Mol Cell Probes 1999; 13: 315-320.
60. Rasoamanana B, Leroy F, Boisier P, Rasolomaharo M, Buchy P, Carniel E et al. Field evaluation of an immunoglobulin G anti-FI enzymelinked immunosorbent assay for serodiagnosis of human plague in Madagascar. Clin Diagn Lab Immunol 1997; 4: 587-591.
61. Inglesby TV, Dennis DT, Hendrerson DA, Barlett JG, Ascher MS, Eitzen E et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283: 2281-2290.
62. Heath DG, Anderson GW Jr: Mauro JM, Welkos SL, Andrews GP, Adamovicz J et al. Protection against experimental bubonic and pneumonic plague by a recombinat capsular FI-V antigen fusion protein vaccine. Vaccine 1998; 16: 1131-1137.
63. Williamson ED. Eley SM, Stagg AJ, Green M, Russell P, Titball RW. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2000; 19: 566-571.
64. Feodorova VA, Devdariani ZL, Nazarova LS. Adjuvant effect of antiidiotypic antibodies to Yersinia pestis lipopolysaccharide. J Med Microbiol 1999; 48: 751-756.
65. Lippi D, Conti AA. Plague, policy, saints and terrorists: a histotical survey. J Infect 2002; 44: 226-228.
66. a ed. Churchill Livingstone. Philadelphia, 2000; Vol 2: 2393-2402.
67. Choi E. Tularemia and Q fever. Med Clin North Am 2002; 86: 393-416.
68. Stewart SJ. Tularemia: association with hunting and farming. FEMS Immunol Med Microbiol 1996; 13: 197-199.
69. Tärnvik A, Sandström G, Sjöstedt A. Epidemiological analysis of tularemia in Sweden 1931-1993. FEMS Immunol Med Microbiol 1996; 13: 201-204.
70. Eiros Bouza JM, Rodríguez Torres A. Tularemia. Rev Clin Esp 1998; 198: 785-788.
71. Bachiller Luque P, Pérez Castrillón JL, Martín Luquero M, Mena Martín JF, de la Lama López-Areal J, Pérez Pascual P et al. Descripción preliminar de un brote epidémico de tularemia en Valladolid. Rev Clin Esp 1998; 198: 789-793.
72. Pérez Castrillón JL, Bachiller Luque P, Martín Luquero M, Mena Martín FJ, Herreros V. Tularemia epidemic in northwest Spain: clinical description and therapeutic response. Clin Infect Dis 2001; 33: 573-576.
73. Eiros JM, Hernández B, Labayru C, Vega T, Ruiz Cosín C. Tularemia: experiencia desde Castilla y León. En: Picazo JJ, Bouza E, eds. Infección 2002. Servisistem 2000 SL. Bilbao, 2002: 243-266.
74. Montejo M, Pérez-Irezábal J, González de Zárate P, Aguirrebengoa K, Vicente JM, Martínez E et al. Tularemia: descripción de 16 casos procedentes de la Comunidad de Castilla y León. Rev Clin Esp 1998; 198: 794-798.
75. a ed), vol 2. Systematic Bacteriology. Edward Arnold. London 1990: 595-597.
76. Gurycova D. First isolation of Francisella tularensis subsp, tularensis in Europe. Eur J Epidemiol 1998; 14: 797-802.
77. Luotonen L, Tapiainen T, Kallioinen M, Luotonen J. Tularemia of the middle ear. Pediatr Infect Dis J 2002; 21: 264-265.
78. Steinemann TL, Sheikholeslami MR, Brown HH, Bradsher RW. Oculoglandular tularemia. Arch Ophthalmol 1999; 117: 132-133.
79. Bellido-Casado J, Pérez-Castrillón JL, Bachiller-Luque P, Martín-Luquero M, Mena-Martín JF, Herreros-Fernández V. Report of five cases of tularemic pneumonia in a tularemia outbreak in Spain. Eur J Clin Microbiol Infect Dis 2000; 19: 218-220.
80. Fernández-Jorge MA, Ramos Casado L. Afectación pulmonar en la tularemia. An Med Interna 2001; 18: 32-34.
81. Shapiro DS, Schwartz DR. Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure. J Clin Microbiol 2002; 40: 2278-2281.
82. Labayru C, Palop A, López-Urrutia L, Avellaneda C, Mazón MA, Alberte A et al. Francisella tularensis: puesta a punto en el diagnóstico microbiológico tras un brote epidémico. Enferm Infecc Microbiol Clin 1999; 17: 458-462.
83. Berdal BP, Mehl R, Haaheim H, Loksa M, Grunow R, Burans J et al. Field detection of Francisella tularensis. Scand J Infect Dis 2000; 32: 287-291.
84. Fournier PE, Bernabeu L, Schubert B, Mutillod M, Roux V, Raoult D. Isolation of Francisella tularensis by centrifugation of shell vial cell culture an inoculation eschar. J Clin Microbiol 1998; 36: 2782-2783.
85. De la Puente Redondo VA, García del Blanco N, Gutiérrez Martín CB, García Peña FJ, Rodríguez Ferri EF. Comparison of different PCR approaches for typing of Francisella tularensis strains. J Clin Microbiol 2000; 38: 1016-1022.
86. Johansson A, Ibrahim A, Goransson I, Eriksson U, Gurycova D, Clarridge JE 3rd et al. Evaluation of PCR-based methods for discrimination of Francisella species and subspecies and development of a specific PCR that distinguishes the two major subspecies of Francisella tularensis. J Clin Microbiol 2000; 38: 4180-4185.
87. Bevanger L, Maeland JA, Kvan AI. Comparative analysis of antibodies eight years later. Clin Diagn Lab Immunol 1994: 1: 238-240.
88. Dueñas AI, Ortega M, Garrote I, de Frutos M, Gutiérrez P, García-Pascual A et al. Diagnóstico de laboratorio y evolución serológica de pacientes con tularemia. Med Clin (Barc) 2000; 114: 407-410.
89. Chocarro A, González A, García I. Treatment of tularemia with ciprofloxacin. Clin Infect Dis 2000; 31: 623.
90. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative for the treatment of tularemia: rewiev of the literature. Clin Infect Dis 1994; 19: 42-47.
91. Risi G, Pombo DJ. Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options. Clin Infect Dis 1995: 20: 174-175.
92. Waag DM, McKee KT, Sandström G, Pratt LI, Bolt CR, England MJ et al. Cell mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin Diag Lab Immunol 1995; 2: 143-148.
93. Havlasova J, Hernychova L, Halada P, Pellantova VV, Krejsek J, Stulik J et al. Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics 2002; 2: 857-867.
94. Rodríguez Torres A. Situation actuelle et problèmes posés par la brucellose humaine. Rev Elev Méd Vét Pays Trop 1987; 40: 335-339.
95. Wallach JC, Samartino LE, Efron A, Baldi PC. Human infection by Brucella melitensis: an outbreak attributed to contact with infected goats. FEMS Immunol Med Microbiol 1997; 19: 315-321.
96. Cloeckaert A, Grayon M, Verger JM, Letesson JJ, Godfroid F. Conservation of seven genes involved in the biosynthesis of the lipopolysaccharide O-side chain in Brucella spp. Res Microbiol 2000; 151: 209-216.
97. Moreno E, Moriyón I. Brucella melitensis: a nasty bug with hidden credentials for virulence. Proc Natl Acad Sci USA 2002; 99: 1-3.
98. Fosgate GT, Carpenter TE, Chomell BB, Case JT, DeBess EE, Reilly KF. Time-space clustering of human brucellosis, California, 1973-1992. Emerg Infect Dis 2002; 8: 672-678.
99. Díaz R, Maravi-Poma E, Fernández JL, García-Merlo S, Rivero-Puente A. Brucelosis: estudio de 222 casos. IV. Diagnóstico de la brucelosis humana. Rev Clin Esp 1982; 166: 107-110.
100. Kubler PA, Klestov AC. Osteoarticular brucellosis with long latent period. Clin Rheumatol 2001; 20: 444-446.
101. Ayala-Gaytán JJ, Ortegón-Baqueiro H, de la Maza M. Brucella melitensis cerebellar abscess. J Infect Dis 1989; 160: 730-732.
102. Helvaci M, Kaslrga E, Cetin N, Yaprak I. Intramedullary spinal cord abscess suspected of Brucella infection. Pediatr Int 2002; 44: 446-448.
103. Aliaga L, Cobo F, Cueto A, Rosa-Fraile M. Pulmonary Infection due to Brucella melitensis. Int J Infect Dis 2001; 5: 232-234.
104. Kadikoylu G, Tuncer G, Bolaman Z, Sina M. Brucellar Orchitis in Innerwest Anatolia Region of Turkey: a report of 12 cases. Urol Int 2002; 69: 33-35.
105. Kula S, Erer D, Buyukates M, Tunaoglu FS, Olgunturk R, Ozdogan EM. Brucella endocarditis: case report and review of the literature. J Heart Valve Dis 2001; 10: 486-488.
106. Gungur K, Bekir NA, Namiduru M. Ocular complications asssociated with brucellosis in an endemic area. Eur J Ophthalmol 2002; 12: 232-237.
107. Navas E, Guerrero A, Cobo J, Loza E. Faster isolation of Brucella spp.from blood by isolator compared with BACTEC NR. Diagn Microbiol Infect Dis 1993; 16: 79-81.
108. Sumerkan B, Gokahmetoglu S, Esel D. Brucella detection in blood: comparison of the BacT/Alert standard aerobic bottle, BacT/Alert FAN aerobic bottle and BacT/Alert enhanced FAN aerobic bottle in simulated blood culture. Clin Microbiol Infect 2001; 7: 369-372.
109. Gotuzzo E, Carrillo C, Guerra J, Losa L. An evaluation of diagnostic methods for brucellosis-the value of bone marrow culture. J Infect Dis 1986; 153: 122-125.
110. Navarro E, Fernández JA, Escribano J, Solera J. PCR assay for diagnosis of human brucellosis. J Clin Microbiol 1999; 37: 1654-1655.
111. Zerva L, Bourantas K, Mitka S. Kansouzidou A, Legakis NJ. Serum is the preferred clinical specimen for diagnosis of human brucellosis by PCR. J Clin Microbiol 2001; 39: 1661-1664.
112. Casanas MC, Queipo-Ortuño MI, Rodríguez Torres A, Orduña A, Colmenero JD, Morata P. Specificity of a polymerase chain reaction assay of a targed sequence on the 31-kilodalton Brucella antigen DNA used to diagnose human brucellosis. Eur J Clin Microbiol Infect Dis 2001; 20: 127-131.
113. Smits HL, Basahi MA, Díaz R, Marrodan T, Douglas JT. Rocha A et al. Development and evaluation of a rapid dipstick assay for serodiagnosis of acute human brucellosis. J Clin Microbiol 1999; 37: 79-82.
114. Osoba AO, Balkhy H, Memish Z, Khan MY, Al-Thagafi A, Al Share B et al. Diagnostic value of Brucella ELISA IgG and IgM in bacteremic and non-bacteremic patients with brucellosis. J Chemother 2001; 13 (Suppl 1): 54-59.
115. Gad El-Rab MO, Kambal AM. Evaluation of a Brucella enzyme immunoassay test (ELISA) in comparison with bacteriological culture and agglutination. J Infect 1998; 36: 197-201.
116. Colmenero JD, Queipo-Ortuño MI. Reguera JM, Suárez-Muñ oz MA, Martín-Carballino S, Morata P. Chronic hepatosplenic abscesses in Brucellosis. Clinico-therapeutic features and molecular diagnostic approach. Diagn Microbiol Infect Dis 2002; 42: 159-167.
117. Yayli G, Isler M, Oyar O. Medically treated splenic due to Brucella. Scand J Infect Dis 2002; 34: 133-135.
118. Miller JM. Agents of bioterrorism. Preparing for bioterrorism at the community health care level. Infect Dis Clin North Am 2001; 15: 1127-1156.
119. Lamb A. Biological weapons: the facts not the fiction. Clin Med 2001; 1: 502-504.
120. Frank SA, Jeffrey JS. The probability of severe disease in zoonotic and commensal infections. Proc R Soc Lond B Biol Sci 2001; 268: 53-60.
121. DelVecchio VG, Kapatral V, Redkar RJ, Patra G, Mujer C, Los T et al. The genome sequence of the facultative intracellular pathogen Brucella melitensis. Proc Natl Acad Sci USA 2002; 99: 443-448.